Formulate and Evaluate Immediate Release Tablet of Antihypertensive Drug

Conventional pills of lisinopril were developed to treat hypertension. The medication was determined to be steady. Additionally, it was verified by FTIR analysis that there is no interaction between the medicine and the excipients due to incompatibility findings in various ratios. The hardness, weight fluctuation, thickness, friability, disintegration, dissolution, and other characteristics of the final tablets were assessed. All of the Lisinopril formulations made using the wet granulation process were subjected to in vitro drug release profiles using a modified dissolution equipment. The temperature was kept at 37±0.5°C. Figure 17 displays the % cumulative medication release graphs. The medication release was determined to be lower because the F1 trial batch needed more time to dissolve and disintegrate. After adding 10 mg of aerosol and 15 mg of sodium starch glycolate to the F3 batch, there was a noticeable increase in drug release. F3 demonstrated a 98.54% drug release in 30 minutes across all of these formulations. It indicates that this formulation produced the highest level of medication release. With 98.54% drug release, the formulation F3 Batch was deemed optimal because it met all pharmaceutical standards and seemed to provide better therapeutic effects. Stability Studies: To ascertain the formulation's physical stability, stability studies were conducted for the improved formulation (F3). The findings demonstrated that the parameters assessed during the research period under expedited settings did not significantly alter.